

1 Article, Special Issue "Induced Pluripotent Stem Cells in Neurodegenerative Diseases: Application for Therapy and  
2 Disease Modeling"

# 3 A simple differentiation protocol for generation of 4 induced pluripotent stem cell-derived basal forebrain 5 cholinergic neurons for Alzheimer's disease and 6 frontotemporal dementia disease modeling

## 7 Supplemental information

### 8 *Method 1. Reprogramming and characterisation of MBE2960 healthy control iPSC line*

9 The iPSCs were generated using skin fibroblasts obtained from subjects over the age of 18 years  
10 by episomal method as described [40]. Briefly, reprogramming was performed on passage 8-10  
11 fibroblasts by nucleofection (Lonza Amaxa Nucleofector) with episomal vectors expressing  
12 *OCT4*, *SOX2*, *KLF4*, *L-MYC*, *LIN28* and shRNA against *p53* [41] in feeder- and serum- free  
13 conditions using TeSR-E7 medium (Stemcell Technologies). Subsequently, reprogrammed  
14 colonies were manually dissected to establish clonal cell lines [42]. Three clones were assessed  
15 for pluripotency markers via immunocytochemistry (Figure S1A). The iPSC line was expanded  
16 and characterised. Embryoid bodies were obtained as described [43] and using tri-lineage  
17 differentiation kit (Stemcell Technologies). Germ layer differentiation was assessed by  
18 immunochemistry (Figure S1B). Copy number variation (CNV) analysis of original fibroblasts  
19 and iPSCs from MBE2960 (Figure S1C) was performed using Illumina HumanCore Beadchip  
20 arrays as we described [40]. CNV analyses were performed using PennCNV and QuantiSNP with  
21 default parameter settings [44,45]. Chromosomal aberrations were deemed to involve at least 10  
22 contiguous single nucleotide polymorphisms (SNPs) or a genomic region spanning at least 1MB  
23 [44,45]. The B allele frequency (BAF) and the log R ratio (LRR) were extracted from  
24 GenomeStudio (Illumina) for representation (Figure S1D).

### 25 *Method 2. Reprogramming and characterization of a late-onset (sporadic) Alzheimer's disease iPSC line* 26 *UOWi006-A and a frontotemporal dementia / amyotrophic lateral sclerosis (FTD/ALS C9orf72 expansion)* 27 *UOWi008-A iPSC line*

28 A skin biopsy was obtained from an 83-year-old female with sporadic Alzheimer's disease (*APOE*  
29  $\epsilon 4/4$  genotype) (RB7-11 clone) and a 66-year-old female patient with diagnosed with  
30 frontotemporal dementia / amyotrophic lateral sclerosis (FTD/ALS, caused by a *C9orf72*  
31 expansion) (C-10 clone), following informed consent from the donor. The study was approved  
32 by the University of Wollongong Human Ethics Committee (HE13/299). Dermal fibroblasts were  
33 cultured at 37°C and 5% CO<sub>2</sub> in Dulbecco's Modified Eagle Medium F12 (DMEM/F12)  
34 supplemented with 1x Non-Essential Amino Acids (Thermo Fisher Scientific) and 10% foetal  
35 bovine serum (Interpath). Fibroblasts were reprogrammed using Stemgent microRNA-Enhanced  
36 mRNA Reprogramming kit (Stemgent) with pluripotency transcription factors Oct4, Klf4, Sox2,  
37 c-Myc, Lin28 and Nanog, following the manufacturer's protocol. Prior to reprogramming,  
38 Pluriton reprogramming medium was conditioned using new-born human foreskin fibroblasts  
39 (Global Stem), as per the reprogramming protocol. Spontaneous iPSC colonies were isolated on  
40 day 14 for expansion into individual iPSC lines (clones). Established iPSC clones were maintained  
41 at 37°C and 5% CO<sub>2</sub> on Matrigel-coated plates in TeSR-E8 and were split 1:5 using dispase on  
42 reaching 70% confluence.

43 The first iPSC colonies appeared on day 10 and were isolated on day 14 for expansion and  
 44 characterisation, with clone 11 selected following confirmation of pluripotency. The iPSC  
 45 colonies had normal morphology (Figure S2A) and karyotype (Figure S2B), with no  
 46 abnormalities detected in 15 cells at 400 bands per haploid set. The identity of iPSCs was  
 47 authenticated against its parental fibroblast line via short tandem repeat (STR) profiling.  
 48 Transcription of endogenous pluripotency genes *NANOG* and *POU5F1* increased by 210 and  
 49 1,300-fold, respectively, in comparison to parental fibroblasts (Figure S2C) and  
 50 immunocytochemical analysis demonstrated expression of pluripotency markers Oct4, SSEA-4  
 51 and TRA-1-60 (Figure S2D). Differentiation potential into the three-germ layers was confirmed  
 52 using the hPSC Scorecard assay (Figure S2E).

53 Characterisation of iPSC colonies via karyotyping, STR analysis, qPCR, immunofluorescence and  
 54 hPSC Scorecard analysis was performed as previously described [15].

55

### 56 *List of genes*


57 Table S1. List of genes analysed in Nanostring for iPSC and BFCN cultures.

Gene name	Approved name	Accession	Position	Category
<i>AARS</i>	Alanyl-tRNA synthetase	NM_001605.2	836-935	Housekeeper
<i>ACHE</i>	Acetylcholinesterase	NM_000665.3	1058-1157	BFCN
<i>ALDOC</i>	Aldolase, fructose-bisphosphate C	NM_005165.2	261-360	Astrocytes
<i>ASB7</i>	Ankyrin repeat and SOCS box containing 7	NM_024708.3	1281-1380	Housekeeper
<i>ASCL1</i>	Achaete-scute homolog 1	NM_004316.3	1651-1750	Neuronal progenitor
<i>CCDC127</i>	Coiled-coil domain-containing 127	NM_145265.2	295-394	Housekeeper
<i>CHAT</i>	Choline O-acetyltransferase	NM_020549.4	1106-1205	BFCN
<i>SLC5A7</i> (CHT1)	Solute carrier family 5 member 7 (choline transporter 1)	NM_021815.2	956-1055	BFCN

<i>CNOT10</i>	CCR4-NOT transcription complex subunit 10	NM_001256741.1	1963-2062	Housekeeper
<i>SLC6A3</i> (DAT1)	Solute carrier family 6 member 3 (dopamine transporter 1)	NM_001044.3	1549-1648	Neuronal
<i>DLX1</i>	Distal-less homeobox 1	NM_001038493.1	1336-1435	Neuronal progenitor
<i>DLX2</i>	Distal-less homeobox 2	NM_004405.3	591-690	Neuronal progenitor
<i>SLC1A3</i> (EAAT1)	Solute carrier family 1 member 3 (glial high affinity glutamate transporter 1)	NM_004172.4	559-658	Astrocytes
<i>EID2</i>	EP3000-interacting inhibitor of differentiation 2	NM_153232.3	566-665	Housekeeper
<i>EMX1</i>	Empty-spiracles homeobox 1	NM_004097.2	1747-1846	Neuronal progenitor
<i>FOXP1</i>	Forkhead box protein G1	NM_005249.3	1401-1500	BFCN progenitor
<i>GAD2</i>	Glutamate decarboxylase 2	NM_000818.2	1246-1345	Neuronal
<i>GRIA1</i>	Glutamate ionotropic receptor AMPA type subunit 1	NM_000827.3	2841-2940	Neuronal
<i>GRIA2</i>	Glutamate ionotropic receptor AMPA type subunit 2	NM_001083620.1	866-965	Neuronal
<i>GRIN1</i>	Glutamate ionotropic receptor NMDA type subunit 1	NM_000832.5	1291-1390	Neuronal


<i>ISL1</i>	Insulin Enhancer protein (ISL) LIM homeobox 1	NM_002202.2	1376-1475	BFCN progenitor
<i>LHX8</i>	LIM homeobox 8	NM_001001933.1	1301-1400	BFCN progenitor
<i>MAP2</i>	Microtubule associated protein 2	NM_031845.2	5171-5270	Neuronal
<i>MTO1</i>	Mitochondrial tRNA translation optimization 1	NM_133645.2	1466-1565	Housekeeper
<i>NANOG</i>	Nanog homeobox	NM_024865.2	1101-1200	Pluripotency
<i>NFIA</i>	Nuclear factor I A	NM_001134673.2	1086-1185	Astrocytes
<i>NGFR</i>	Nerve growth factor receptor	NM_002507.3	2731-2830	BFCN
<i>NKX2-1</i>	NK2 homeobox 1	NM_003317.3	2012-2111	BFCN progenitor
<i>NTRK1 (TRKA)</i>	Neurotrophic receptor tyrosine kinase 1	NM_001012331.1	1366-1465	BFCN
<i>PAX6</i>	Paired box 6	NM_000280.3	1174-1273	Neuronal progenitor
<i>POUF51</i>	POU class 5 homeobox 1	NM_002701.4	1226-1325	Pluripotency
<i>DLG4 (PSD95)</i>	Disc large MAGUK scaffold protein 4 (post-synaptic density protein 95)	NM_001365.3	2461-2560	Neuronal
<i>RABEP2</i>	Rabaptin, RAB GTPase-binding effector protein 2	NM_024816.2	1783-1882	Housekeeper

<i>S100B</i>	S100 calcium binding protein B	NM_006272.2	305-404	Astrocytes
<i>SOX1</i>	SRY-box 1	NM_005986.2	1496-1595	Neuronal progenitor
<i>SUPT7L</i>	SPT7 like, STAGA complex gamma subunit	NM_014860.2	1171-1270	Housekeeper
<i>SYN1</i>	Synapsin I	NM_006950.3	566-665	Neuronal
<i>TADA2B</i>	Transcriptional adaptor 2B	NM_152293.2	1589-1688	Housekeeper
<i>TH</i>	Tyrosine hydroxylase	NM_000360.3	1307-1406	Neuronal
<i>TUBB3</i>	Tubulin beta 3 class III	NM_006086.2	1538-1637	Neuronal
<i>SL18A3 (VACHT)</i>	Solute carrier family 18 member A3 (vesicular acetylcholine transporter)	NM_003055.2	1651-1750	BFCN
<i>ZNF324B</i>	Zinc finger protein 324B	NM_207395.2	2821-2920	Housekeeper



59

60 Figure S1. Confirmation of pluripotency of iPSCs MBE2960 healthy control. A. iPSC colonies were  
 61 positive for the immunocytochemical staining for pluripotency markers TRA-1-60 (Red) and Oct-  
 62 4 (Green) with DAPI (Blue). B. iPSCs were differentiated into the three germ layers and confirmed  
 63 via immunocytochemical staining for AFP (Endoderm), SMA (Mesoderm) and Nestin  
 64 (Ectoderm) with DAPI. C. Copy number variation (CNV) analysis of original fibroblasts and  
 65 iPSCs from MBE2960 D. Representation of the B allele frequency (BAF) and the log R ratio (LRR)  
 66 of the fibroblasts and the iPSC clones. Scale bars = 20  $\mu$ m.



67

68

69

70

71

72


73

74

75

76

Figure S2. Confirmation of pluripotency and three germ layer differentiation of iPSCs RB7-11 late-onset Alzheimer’s disease (UOWi006-A). iPSC colonies showed normal A. morphology and B. karyotype. C. RT-qPCR analysis demonstrated fold change in expression of pluripotency transcription factors *NANOG* and *POU5F1* to parental fibroblasts. D. Immunocytochemical staining for pluripotency markers Oct4, SSEA-4 and TRA-1-60 (green) with RedDot2 nuclear marker (red) or brightfield. E. Three germ layer differentiation showed fold change (fc) in expression for specific sets of genes for self-renewal and ectoderm, mesoderm and endoderm germ layers based on TaqMan hPSC Scorecard. Data points on graph represent technical replicates on RT-qPCR. Scale bars = 50  $\mu$ m.



77

78

79

80

81

82

83

84

85

86

87


88

89

90

Figure S3. Confirmation of pluripotency and three germ layer differentiation of iPSCs C-10 FTD/ALS (UOWi008-A). The hexanucleotide repeat in C9orf72 was genotyped using the repeat primed polymerase chain reaction (PCR) method described by Renton et al. (2011), with a pathogenic expansion defined as more than 30 repeat units. Fragment length analysis was performed by MacroGen Inc (South Korea) using the ABI 3730XL DNA analyser (Applied Biosystems, CA, USA) and data were analysed using Peak Scanner 2 (Life Technologies). A. Cells showed normal karyotype B. and morphology C. Immunocytochemical staining for pluripotency markers Oct4, SSEA-4 and TRA-1-60 (green) with RedDot2 nuclear marker (red) or brightfield D.. RT-qPCR analysis demonstrated fold change in expression of pluripotency transcription factors *NANOG* and *POU5F1* to parental fibroblasts. E. Three germ layer differentiation showed fold change (fc) in expression for specific sets of genes for self-renewal and ectoderm, mesoderm and endoderm germ layers based on TaqMan hPSC Scorecard F. Data points on graph represent technical replicates on RT-qPCR. Scale bars = 50  $\mu$ m.





91

92

93


94

95

96

97


Figure S4. RNA molecule count of housekeeper genes. iPSCs, NPCs and BFCNs samples were analysed by nCounter (Nanosttring) and results are shown as RNA molecule count after internal quality control and normalisation to a reference sample used on the PlexSet. The ten housekeeper genes *AARS*, *ASB7*, *CCDC127*, *CNOT10*, *EID2*, *MTO1*, *RABEP2*, *SUPT7L*, *TADA2B* and *ZNF324B* were analysed. The overall housekeeper expression between iPSCs, NPCs and BFCNs shows no significant difference.



98

99  
100  
101  
102


Figure S5. RNA molecule count of pluripotency markers. iPSCs, NPCs and BFCNs samples were analysed by nCounter (Nanostring) and results are shown as RNA molecule count after normalisation of total amount of RNA molecules to the housekeeper genes. The pluripotency markers *NANOG* and *POU5F1* were analysed.



103

104  
105  
106  
107

Figure S6. RNA molecule count of developmental markers. iPSCs, NPCs and BFCNs samples were analysed by nCounter (Nanostring) and results are shown as RNA molecule count after normalisation of total amount of RNA molecules to the housekeeper genes. The developmental markers *ASCL1*, *DLX1*, *DLX2*, *EMX1*, *PAX6* and *SOX1* were analysed.



108


109

110

111

112

Figure S7. RNA molecule count of cholinergic developmental markers. iPSCs, NPCs and BFCNs samples were analysed by nCounter (Nanostring) and results are shown as RNA molecule count after normalisation of total amount of RNA molecules to the housekeeper genes. The cholinergic developmental markers *FOXP1*, *ISL1*, *LHX8* and *NKX2-1* were analysed.



113

114


115

116

117


118

Figure S8. RNA molecule count of neuronal markers. iPSCs, NPCs and BFCNs samples were analysed by nCounter (Nanostring) and results are shown as RNA molecule count after normalisation of total amount of RNA molecules to the housekeeper genes. The neuronal markers *SLC6A3* (DAT1), *GAD2*, *GRIA1*, *GRIA2*, *GRIN1*, *MAP2*, *DLG4* (PSD95), *SYN1*, *TH* and *TUBB3* were analysed.



119

120 Figure S9. RNA molecule count of cholinergic neuron markers. iPSCs, NPCs and BFCNs samples  
 121 were analysed by nCounter (Nanostring) and results are shown as RNA molecule count after  
 122 normalisation of total amount of RNA molecules to the housekeeper genes. The cholinergic  
 123 neuronal markers *ACHE*, *CHAT*, *SLC5A7 (CHT1)*, *NGFR*, *NTRK1 (TRKA)* and *SLC18A3*  
 124 (*VACHT*) were analysed.



125

126 Figure S10. RNA molecule count of astrocytic markers. iPSCs, NPCs and BFCNs samples were  
 127 analysed by nCounter (Nanostring) and results are shown as RNA molecule count after  
 128 normalisation of total amount of RNA molecules to the housekeeper genes. The astrocytic  
 129 markers *ALDOC*, *SLC1A3 (EAAT1)*, *NFIA* and *S100B* were analysed.

130

131



© 2020 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).